Clinical Trial Detail

NCT ID NCT02630693
Title Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Canadian Cancer Trials Group
Indications

Her2-receptor negative breast cancer

Therapies

Palbociclib

Fulvestrant

Tamoxifen

Age Groups: adult

Additional content available in CKB BOOST